Comment from Anonymous

This comment is submitted in support of the request for a precautionary principle warning regarding acetaminophen use during pregnancy, including and especially acetaminophen exposure during labor and delivery before clamping of the umbilical cord. Attached is a PDF copy of Tylenol and Autism: Evidence, Scientific Blunders, and Medicine Gone Wrong by William Parker, PhD. The book is highly relevant to the issues raised in this petition because it collects, organizes, and discusses a large body of evidence concerning acetaminophen exposure during fetal and early-life neurodevelopment, including evidence related to pregnancy, labor and delivery, cord-blood exposure, immature neonatal metabolism, oxidative stress, susceptibility, animal evidence, and interpretation of the human epidemiologic literature. This comment is not intended to ask FDA to rely on the book itself as dispositive evidence. Rather, the attached volume serves as a comprehensive index and synthesis of the underlying scientific literature, with citations to the original studies provided in the notes section beginning on page 225. The book may therefore assist FDA in identifying, reviewing, and contextualizing the underlying peer-reviewed evidence relevant to the requested pregnancy warning. Several sections are particularly relevant to the pregnancy petition. Chapter 5, beginning on page 81, addresses the timing of risk during pregnancy, labor and delivery, and the immediate postnatal period. This section is especially important because many discussions of acetaminophen and neurodevelopment focus narrowly on maternal use during pregnancy while giving insufficient attention to exposure during labor and delivery before cord clamping, even though the fetus may be directly exposed during a highly vulnerable developmental period. Chapter 3, beginning on page 43, addresses a recurring problem in the interpretation of pregnancy studies: treating factors related to oxidative stress, inflammation, infection, pain, fever, chronic illness, or other biologically relevant susceptibility factors as ordinary confounders rather than as potential interacting variables. This distinction is central to the petition because over-adjustment for such variables may obscure the very biological pathway through which acetaminophen could increase risk in susceptible pregnancies. Chapter 6, beginning on page 97, summarizes laboratory animal evidence relevant to developmental neurotoxicity. This section is relevant because it collects multiple lines of experimental evidence suggesting that early-life acetaminophen exposure can produce persistent neurodevelopmental or behavioral effects in animals, including effects at doses Parker describes as comparable to, or lower than, doses used in human infants and children. Pages 139-142 discuss recent work concerning N-acetyl-p-benzoquinone imine (NAPQI), the toxic metabolite of acetaminophen, and preliminary evidence of acetaminophen-related adduct formation in neonatal brain tissue. This is highly relevant because it speaks directly to biological plausibility and to the question whether acetaminophen metabolites can reach or form within developing brain tissue during early-life vulnerability. Appendix B, pages 189-194, provides concise evidence summary tables that organize the evidence into pharmacologic, epidemiologic, laboratory animal, and miscellaneous lines of evidence. Those tables may be useful to FDA as a roadmap for reviewing the underlying literature cited throughout the book. For these reasons, the attached book should be included in the administrative record and considered as a source guide and synthesis relevant to the requested precautionary warning for acetaminophen use during pregnancy, including acetaminophen exposure during labor and delivery before cord clamping.